Biomedical subjects

S Kes

Publications and source records attributed to S Kes.

40 records · Page 3Linked to original sources

PubMed1990

De Vega's tricuspid annuloplasty: analysis of 195 patients.

In the years 1984-1989, 195 De Vega tricuspid annuloplasties were performed in association with mitral or mitral-aortic valve procedures. Preoperatively, 9 patients (4.6%) were in New York Heart Association functional class II, 124 (63.6%) were in class III, and the remaining 62 (31.8%) were in class IV. Tricuspid insufficiency was recognized by routine digital palpation of the tricuspid valve during the operation in 42 (21.5%) of the patients. Hospital mortality rate was 7.6% (15 patients). Late deaths occurred in 6 (3.0%) cases during a follow-up period of 3 to 72 months (mean 42 months). 8 patients (4.1%) required reoperation. Tricuspid annuloplasty failure was observed in 4 patients (2%). These valves were replaced with biological valves in three patients and with a mechanical valve in one patient. 112 of the survivors (64.3%) were evaluated by echocardiography and/or right ventriculography. Analysis of postoperative data showed that in 84 of the 112 patients (75%) tricuspid regurgitation disappeared completely after annuloplasty, 88% of surviving patients were in functional class I or II. For the series presented actuarial survival rate at 6 years was 79.1% +/- 14.4%. In the light of this study we recommend De Vega's annuloplasty as the method of choice for moderate to severe functional tricuspid insufficiency.

Adolescent↗

PubMed1977

HB-Ag in sweat.

Thirty patients were studied at the Hacettepe University Medical Center. Ten patients had hepatic cirrhosis, 20 patients had viral hepatitis. HB-Ag in the serum was positive in all patients by the counterimmunoelectrophoresis method. One and a half milliliters of sweat was collected from each patient, dried and dissolved in 0.2 ml. of buffer solution. HB-Ag was positive in all patients by radioimmunoassay method. This study indicates that direct contact is one of the most important factors in the epidemiology of the disease and this may even be more important in asymptomatic carriers.

Adolescent↗

PubMedDate not supplied

Angiotensin converting enzyme gene polymorphism and the risk and extent of ischemic heart disease among Turkish patients.

OBJECTIVE: To evaluate the effects of the angiotensin converting enzyme gene polymorphism on the presence and extent of coronary artery disease and myocardial infarction among Turkish patients. METHODS: In total 393 consecutive patients undergoing coronary angiography were evaluated for cardiac risk factors including the lipoprotein profile, lipoprotein (a), apoprotein B, and apoprotein A1 levels. The angiotensin converting enzyme genotype was determined by polymerase chain reaction. The extent of coronary atherosclerosis was determined from the angiograms using the Gensini and Leaman scores. RESULTS: The angiotensin converting enzyme genotype was found not to be associated either with coronary artery disease (odds ratio 0.81, P > 0.05) or with myocardial infarction (odds ratio 1.16, P > 0.05). Exclusion of high-risk individuals failed to reveal any association for these subgroups. Furthermore, there was no association between aneurysm formation and the genotype (P > 0.05). The lipid parameters were also not affected by the genotype (P > 0.05). However, the extent of coronary atherosclerosis determined by the Gensini score was related significantly to the genotype by multivariate analysis (P = 0.007). CONCLUSION: The DD genotype is not associated with coronary artery disease and myocardial infarction among these angiographically assessed Turkish patients, even when low-risk subgroups are analysed. Nonetheless, the extent of coronary atherosclerosis in patients with coronary artery disease is affected by their genotype.

Alleles↗

PubMedDate not supplied

Verapamil SR and trandolapril combination therapy is safe and effective in hypertensive patients with metabolic disorders.

Verapamil SR (180 mg) plus trandolapril (2 mg) is a potent antihypertensive combination but the efficacy and safety of this treatment has not been studied fully in hypertensive patients with metabolic disorders. We enrolled 298 patients with mild to moderate hypertension who had at least one of the following disorders: diabetes mellitus, hypercholesterolaemia or mild renal failure. The sitting systolic pressure and diastolic blood pressures were significantly decreased after 12 weeks of treatment. Blood pressure was inadequately controlled in only 24 patients (8.8%). Progressive decreases in blood glucose, total cholesterol, low-density lipoprotein and triglyceride levels were observed during the study. There was no significant change in blood urea nitrogen, creatinine and transaminase levels (p > 0.05). There was a significant decrease in microalbuminuria levels. There was no significant change in glycosylated haemoglobin levels in diabetic patients. Verapamil SR plus trandolapril is an effective drug combination in the treatment of hypertension. It may be used safely in patients with diabetes mellitus, hyperlipidaemia and mild renal failure.

Adult↗